Single patient compassionate use of X-pact for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This is a special one-time experimental treatment for a single person with prostate cancer, given when other treatments have not worked. It uses a drug called X-PACT as a rescue approach, and only the patient it was designed for can receive it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be the single patient this treatment was designed for.
- You must be willing and able to provide informed consent.
- This is a special 'compassionate use' pathway, so only one patient can receive it.
- You must be under the care of the study doctor at Johns Hopkins.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This trial tests two new investigational drugs, JANX013 and JANX007, together in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination is safe and effective.
This study tests a new drug called xaluritamig for men with advanced prostate cancer that has not responded well to a standard treatment called lutetium-177. The goal is to see if this drug can help control the cancer when other treatments haven't worked well enough.
This Phase 1 trial tests a small-molecule treatment that carries radioactive material to help treat prostate cancer that has spread and keeps growing despite standard hormone-blocking treatment. It’s mainly looking to find a safe dose and see how well the approach works in people with limited treatment options.
This study tests a new investigational medicine for prostate cancer that has spread and is no longer controlled by standard hormone therapy. The drug may work by targeting a protein on cancer cells, and the trial will check if it can shrink the cancer or slow its growth.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.